Defense mechanisms against infections

Herbert Reynolds

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Respiratory infections remain common and may be more difficult to treat because new microbes have been identified; commensal flora can become pathogens; and antibiotic resistance is developing, especially to Streptococcus pneumoniae. Contributing to the severity of pneumonia is the increasing number of more susceptible hosts-immunodeficient patients, created as a by-product of modern medical therapy or from infection with HIV, and elderly patients who have associated illnesses. Better strategies to replete immunocompromised hosts are required. Vaccination to modify infection with S. pneumoniae must be given higher priority by health care providers. New means to immunize the respiratory mucosal surface are needed. Research approaches to consider involve 1) targeting (carrying) relevant antigens to appropriate antigen-processing cells in the airways, eg, dendritic cells; and 2) coupling the immunomodulatory effects of cytokines, eg, interleukin-12. Interleukin-12, for example, can stimulate mucosal antibody responses producing S-IgA and IgG and cause T lymphocytes to produce interferon-γ that can enhance microbial killing by macrophages. Curr Opin Pulm Med 1999, 5:136-142

Original languageEnglish (US)
Pages (from-to)136-142
Number of pages7
JournalCurrent Opinion in Pulmonary Medicine
Volume5
Issue number3
DOIs
StatePublished - Jan 1 1999

Fingerprint

Interleukin-12
Pneumococcal Infections
Antigen Presentation
Immunocompromised Host
Microbial Drug Resistance
Streptococcus pneumoniae
Infection
Respiratory Tract Infections
Health Personnel
Dendritic Cells
Immunoglobulin A
Interferons
HIV Infections
Antibody Formation
Pneumonia
Vaccination
Immunoglobulin G
Macrophages
Cytokines
T-Lymphocytes

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Reynolds, Herbert. / Defense mechanisms against infections. In: Current Opinion in Pulmonary Medicine. 1999 ; Vol. 5, No. 3. pp. 136-142.
@article{3035fd15eba2403295540e9d72937cd2,
title = "Defense mechanisms against infections",
abstract = "Respiratory infections remain common and may be more difficult to treat because new microbes have been identified; commensal flora can become pathogens; and antibiotic resistance is developing, especially to Streptococcus pneumoniae. Contributing to the severity of pneumonia is the increasing number of more susceptible hosts-immunodeficient patients, created as a by-product of modern medical therapy or from infection with HIV, and elderly patients who have associated illnesses. Better strategies to replete immunocompromised hosts are required. Vaccination to modify infection with S. pneumoniae must be given higher priority by health care providers. New means to immunize the respiratory mucosal surface are needed. Research approaches to consider involve 1) targeting (carrying) relevant antigens to appropriate antigen-processing cells in the airways, eg, dendritic cells; and 2) coupling the immunomodulatory effects of cytokines, eg, interleukin-12. Interleukin-12, for example, can stimulate mucosal antibody responses producing S-IgA and IgG and cause T lymphocytes to produce interferon-γ that can enhance microbial killing by macrophages. Curr Opin Pulm Med 1999, 5:136-142",
author = "Herbert Reynolds",
year = "1999",
month = "1",
day = "1",
doi = "10.1097/00063198-199905000-00003",
language = "English (US)",
volume = "5",
pages = "136--142",
journal = "Current Opinion in Pulmonary Medicine",
issn = "1070-5287",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

Defense mechanisms against infections. / Reynolds, Herbert.

In: Current Opinion in Pulmonary Medicine, Vol. 5, No. 3, 01.01.1999, p. 136-142.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Defense mechanisms against infections

AU - Reynolds, Herbert

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Respiratory infections remain common and may be more difficult to treat because new microbes have been identified; commensal flora can become pathogens; and antibiotic resistance is developing, especially to Streptococcus pneumoniae. Contributing to the severity of pneumonia is the increasing number of more susceptible hosts-immunodeficient patients, created as a by-product of modern medical therapy or from infection with HIV, and elderly patients who have associated illnesses. Better strategies to replete immunocompromised hosts are required. Vaccination to modify infection with S. pneumoniae must be given higher priority by health care providers. New means to immunize the respiratory mucosal surface are needed. Research approaches to consider involve 1) targeting (carrying) relevant antigens to appropriate antigen-processing cells in the airways, eg, dendritic cells; and 2) coupling the immunomodulatory effects of cytokines, eg, interleukin-12. Interleukin-12, for example, can stimulate mucosal antibody responses producing S-IgA and IgG and cause T lymphocytes to produce interferon-γ that can enhance microbial killing by macrophages. Curr Opin Pulm Med 1999, 5:136-142

AB - Respiratory infections remain common and may be more difficult to treat because new microbes have been identified; commensal flora can become pathogens; and antibiotic resistance is developing, especially to Streptococcus pneumoniae. Contributing to the severity of pneumonia is the increasing number of more susceptible hosts-immunodeficient patients, created as a by-product of modern medical therapy or from infection with HIV, and elderly patients who have associated illnesses. Better strategies to replete immunocompromised hosts are required. Vaccination to modify infection with S. pneumoniae must be given higher priority by health care providers. New means to immunize the respiratory mucosal surface are needed. Research approaches to consider involve 1) targeting (carrying) relevant antigens to appropriate antigen-processing cells in the airways, eg, dendritic cells; and 2) coupling the immunomodulatory effects of cytokines, eg, interleukin-12. Interleukin-12, for example, can stimulate mucosal antibody responses producing S-IgA and IgG and cause T lymphocytes to produce interferon-γ that can enhance microbial killing by macrophages. Curr Opin Pulm Med 1999, 5:136-142

UR - http://www.scopus.com/inward/record.url?scp=0033124371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033124371&partnerID=8YFLogxK

U2 - 10.1097/00063198-199905000-00003

DO - 10.1097/00063198-199905000-00003

M3 - Article

C2 - 10228737

AN - SCOPUS:0033124371

VL - 5

SP - 136

EP - 142

JO - Current Opinion in Pulmonary Medicine

JF - Current Opinion in Pulmonary Medicine

SN - 1070-5287

IS - 3

ER -